EA201270449A1 - Фармацевтическая композиция для лечения связанных с мср-1 воспалительных заболеваний - Google Patents

Фармацевтическая композиция для лечения связанных с мср-1 воспалительных заболеваний

Info

Publication number
EA201270449A1
EA201270449A1 EA201270449A EA201270449A EA201270449A1 EA 201270449 A1 EA201270449 A1 EA 201270449A1 EA 201270449 A EA201270449 A EA 201270449A EA 201270449 A EA201270449 A EA 201270449A EA 201270449 A1 EA201270449 A1 EA 201270449A1
Authority
EA
Eurasian Patent Office
Prior art keywords
mcp
pharmaceutical composition
inflammatory diseases
treatment
diseases associated
Prior art date
Application number
EA201270449A
Other languages
English (en)
Other versions
EA021485B1 (ru
Inventor
Анджело Гильельмотти
Беатриче Гарроне
Алессандро Бле'
Джузеппе Бьонди
Original Assignee
Ацьенде Кимике Рьюните Анджелини Франческо А.К.Р.А.Ф. С.П.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ацьенде Кимике Рьюните Анджелини Франческо А.К.Р.А.Ф. С.П.А. filed Critical Ацьенде Кимике Рьюните Анджелини Франческо А.К.Р.А.Ф. С.П.А.
Publication of EA201270449A1 publication Critical patent/EA201270449A1/ru
Publication of EA021485B1 publication Critical patent/EA021485B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Изобретение относится к фармацевтической композиции, включающей комбинацию производного 1-бензил-3-гидроксиметилиндазола, понижающего давление средства, выбранного из ингибиторов АСЕ, ингибиторов ренина, ARB и ССВ, и/или средства, понижающего уровень холестерина, выбираемого из производных статина. Комбинация демонстрирует аддитивную и синергетическую активность в снижении уровней МСР-1, таким образом существенно улучшая ингибирование воспалительной реакции и вследствие этого уменьшая осложнения, возникающие у пациентов, страдающих воспалительными заболеваниями.
EA201270449A 2009-09-23 2010-09-03 Фармацевтическая композиция для лечения связанных с мср-1 воспалительных заболеваний EA021485B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09425368 2009-09-23
PCT/EP2010/062979 WO2011036047A1 (en) 2009-09-23 2010-09-03 Pharmaceutical composition for the treatment of mcp-1 mediated inflammatory diseases

Publications (2)

Publication Number Publication Date
EA201270449A1 true EA201270449A1 (ru) 2012-08-30
EA021485B1 EA021485B1 (ru) 2015-06-30

Family

ID=41722750

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201270449A EA021485B1 (ru) 2009-09-23 2010-09-03 Фармацевтическая композиция для лечения связанных с мср-1 воспалительных заболеваний

Country Status (25)

Country Link
US (1) US9492542B2 (ru)
EP (1) EP2480224B1 (ru)
JP (2) JP2013505278A (ru)
KR (1) KR101774402B1 (ru)
CN (1) CN102573827B (ru)
AR (1) AR078307A1 (ru)
AU (1) AU2010297405B2 (ru)
BR (1) BR112012006149A2 (ru)
CA (1) CA2760180C (ru)
CY (1) CY1119125T1 (ru)
DK (1) DK2480224T3 (ru)
EA (1) EA021485B1 (ru)
ES (1) ES2637024T3 (ru)
GE (1) GEP20146067B (ru)
HR (1) HRP20171209T1 (ru)
HU (1) HUE033102T2 (ru)
IL (1) IL218001A (ru)
LT (1) LT2480224T (ru)
MX (1) MX347957B (ru)
PL (1) PL2480224T3 (ru)
PT (1) PT2480224T (ru)
SG (2) SG10201405408YA (ru)
SI (1) SI2480224T1 (ru)
UA (1) UA108742C2 (ru)
WO (1) WO2011036047A1 (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009221063B2 (en) 2008-03-07 2013-03-21 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of MCP-1, and CX3CR1
US8461194B2 (en) 2008-03-07 2013-06-11 Aziende Chimiche Riunite Angelini Francesco A. C. R. A. F. S. P. A. 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of MCP-1, CX3CR1 and P40
US8999292B2 (en) 2012-05-01 2015-04-07 Translatum Medicus Inc. Methods for treating and diagnosing blinding eye diseases
US11221321B2 (en) * 2019-05-29 2022-01-11 Imam Abdulrahman Bin Faisal University Liquid chromatographic method for the simultaneous analysis of antihypertensive and antilipidemic agents and interactions thereof
WO2020261158A1 (en) 2019-06-25 2020-12-30 Translatum Medicus Inc. Processes of making 2-((1-benzyl-1h-indazol-3-yl)methoxy)-2-methylpropanoic acid and its derivatives

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0486478A3 (en) 1984-08-06 1992-08-12 The Upjohn Company Renin-inhibiting peptides
MY103189A (en) 1986-10-31 1993-05-29 Pfizer Nor-statine and nor-cyclostatine polypeptides
US4927807A (en) 1987-10-06 1990-05-22 Abbott Laboratories Glaucoma treatment
IT1230441B (it) 1989-02-07 1991-10-23 Acraf Eteri della serie dell'indazolo
CA2023099A1 (en) 1989-09-04 1991-03-05 Quirico Branca Amino acid derivatives
US5209933A (en) 1990-01-10 1993-05-11 Syntex (U.S.A.) Inc. Long acting calcium channel blocker composition
IE68045B1 (en) 1990-05-11 1996-05-15 Abbott Lab Renin inhibitors
TW198712B (ru) 1991-04-17 1993-01-21 Hoffmann La Roche
IT1253703B (it) * 1991-04-22 1995-08-23 Angelini Francesco Ist Ricerca Uso di acidi metossi alcanoici dell'indazolo per preparare un farmaco attivo nel trattamento di malattie autoimmunitarie
MY119161A (en) 1994-04-18 2005-04-30 Novartis Ag Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities
US5994348A (en) * 1995-06-07 1999-11-30 Sanofi Pharmaceutical compositions containing irbesartan
IT1276031B1 (it) 1995-10-31 1997-10-24 Angelini Ricerche Spa Composizione farmaceutica per il trattamento delle malattie autoimmuni
SE9600120D0 (sv) 1996-01-15 1996-01-15 Astra Ab Novel medical use
IT1293795B1 (it) * 1997-07-28 1999-03-10 Angelini Ricerche Spa Farmaco attivo nel ridurre la produzione di proteina mcp-1
US6268377B1 (en) 1998-09-28 2001-07-31 Merck & Co., Inc. Method for treating androgen-related conditions
GB0111077D0 (en) 2001-05-04 2001-06-27 Biochemie Gmbh Organic compounds
US20030073705A1 (en) 2001-05-14 2003-04-17 Shahnaz Shahinfar Method of treatment
US20030060500A1 (en) * 2001-09-19 2003-03-27 Francois Mach Facilitating organ transplantation with statins (HMG-CoA reductase inhibitors)
US7183285B2 (en) 2004-04-29 2007-02-27 Pharmix Corp. Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
US20070060549A1 (en) 2004-08-10 2007-03-15 Friesen Albert D Combination therapies employing ace inhibitors and uses thereof for the treatment of diabetic disorders
US20060046996A1 (en) 2004-08-31 2006-03-02 Kowa Co., Ltd. Method for treating hyperlipidemia
EP1806137A4 (en) * 2004-10-29 2011-03-30 Kowa Co THERAPEUTIC AGENT FOR THE TREATMENT OF GLOMERULAR DISEASE
ES2448424T3 (es) 2006-02-07 2014-03-13 Mochida Pharmaceutical Co., Ltd. Composición para prevenir la recurrencia de accidente cerebrovascular
WO2008084504A2 (en) 2007-01-12 2008-07-17 Rubicon Research Private Limited Pharmaceutical compositions of angiotensin ii receptor blockers
MX2009009234A (es) * 2007-03-01 2009-12-01 Probiodrug Ag Uso nuevo de inhibidores de ciclasa de glutaminilo.
LT2254869T (lt) 2008-03-07 2017-08-10 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. Nauji 1-benzil-3-hidroksimetilindazolo dariniai ir jų panaudojimas gydyme ligų, susijusių su cx3cr1 ir p40 raiška
AU2009221063B2 (en) 2008-03-07 2013-03-21 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of MCP-1, and CX3CR1
US8461194B2 (en) 2008-03-07 2013-06-11 Aziende Chimiche Riunite Angelini Francesco A. C. R. A. F. S. P. A. 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of MCP-1, CX3CR1 and P40

Also Published As

Publication number Publication date
IL218001A (en) 2015-10-29
SG10201405408YA (en) 2014-10-30
SI2480224T1 (sl) 2017-10-30
IL218001A0 (en) 2012-04-30
AR078307A1 (es) 2011-10-26
KR101774402B1 (ko) 2017-09-04
EP2480224A1 (en) 2012-08-01
CY1119125T1 (el) 2018-02-14
HUE033102T2 (en) 2017-11-28
GEP20146067B (en) 2014-03-25
MX347957B (es) 2017-05-16
JP2013505278A (ja) 2013-02-14
JP2016028026A (ja) 2016-02-25
HRP20171209T1 (hr) 2017-10-20
AU2010297405A1 (en) 2012-03-01
LT2480224T (lt) 2017-08-25
WO2011036047A1 (en) 2011-03-31
CN102573827A (zh) 2012-07-11
SG178414A1 (en) 2012-03-29
CA2760180A1 (en) 2011-03-31
PT2480224T (pt) 2017-07-18
ES2637024T3 (es) 2017-10-10
KR20120090988A (ko) 2012-08-17
DK2480224T3 (en) 2017-09-04
CN102573827B (zh) 2016-08-31
US9492542B2 (en) 2016-11-15
AU2010297405B2 (en) 2016-05-26
US20120220636A1 (en) 2012-08-30
MX2012003485A (es) 2012-04-19
PL2480224T3 (pl) 2017-10-31
BR112012006149A2 (pt) 2016-06-28
UA108742C2 (uk) 2015-06-10
EP2480224B1 (en) 2017-05-24
EA021485B1 (ru) 2015-06-30
JP6122470B2 (ja) 2017-04-26
CA2760180C (en) 2017-07-25

Similar Documents

Publication Publication Date Title
PH12018500768A1 (en) Purin derivatives for use in the treatment of fab-related diseases
MA32393B1 (fr) Composés et compositions servant d'inhibiteurs de kinases
MY185103A (en) Bezylamine derivatives as inhibitors of plasma kallikrein
MX2011011854A (es) Dihidropirimidinonas para uso como inhibidores de la bace2.
EA201100391A1 (ru) Соединения, ингибирующие активность семикарбазид-чувствительной аминооксидазы
NO20065847L (no) Difenylimidazopyrimidiner og -imidazolaminer som inhibitorer av B-sekretase
EA201001412A1 (ru) Ингибиторы киназы pim и способы их применения
EA201290191A1 (ru) N1-ПИРАЗОЛОСПИРОКЕТОНОВЫЕ ИНГИБИТОРЫ АЦЕТИЛ-KoA-КАРБОКСИЛАЗЫ
EA201270215A1 (ru) Apaf-1 ингибиторные соединения
EA200970542A1 (ru) ИНГИБИТОРЫ ДЕЙСТВИЯ Akt
MX350761B (es) Inhibidores de isoindolinona de fosfatidilinositol 3-cinasa.
UA108887C2 (xx) Кристалічна форма бензил-бензольного інгібітора sglt2
MX2012000766A (es) Compuestos triazolopiridina, y su accion como inhibidor de prolil hidroxilasa e inductor de la produccion de eritropoyetina.
WO2008157537A3 (en) Compositions and methods of use for treating or preventing lipid related disorders
WO2008148074A3 (en) Inhibitors of mtor and methods of treatment using same
EA201100138A1 (ru) 4-феноксиметилпиперидины в качестве модуляторов активности gpr119
WO2009093119A3 (en) Use of serine protease inhibitors in the treatment of skin diseases
EA201290516A1 (ru) Гетероароматические производные соединения фенилимидазола в качестве ингибиторов фермента pde10a
WO2009068659A3 (en) Novel disease treatment by predicting drug association
TN2012000458A1 (en) Uses of dgat1 inhibitors
CY1119125T1 (el) Φαρμακευτικη συνθεση για τη θεραπεια προκαλουμενων απο mcp-1 φλεγμονωδων νοσων
UY33221A (es) MÉTODOS PARA TRATAR CÁNCER USANDO INHIBIDORES DE PI3K Y mTOR EN COMBINACIÓN CON INHIBIDORES DE AUTOFAGIA
WO2007117560A3 (en) Piperidine and morpholine renin inhibitors
WO2007081808A3 (en) Compounds and derivatives for the treatment of medical conditions by modulating hormone-sensitive lipase activity
WO2008073466A3 (en) Alpha b-crystallin as a therapy for inflammation

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU